A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction

Trial Profile

A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs CSL 112 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions
  • Acronyms AEGIS-I
  • Sponsors CSL Behring
  • Most Recent Events

    • 15 Nov 2017 Results of substudy (n=63) presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2017 Results evaluating the role of Clinical Events Adjudication Committee in the identification of important clinical endpoints that went initially unreported presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 30 Aug 2017 Results assessing PK and PD profile of CSL112 after 1st infusion in subjects who had an AMI and participated in the AEGIS-I PKPD substudy presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top